Bar-Ilan University joins €8 million European consortium to make life-saving CAR-T cancer therapy faster, safer, and more accessible
Business Announcement
Updates every hour. Last Updated: 10-Sep-2025 07:11 ET (10-Sep-2025 11:11 GMT/UTC)
Bar-Ilan University has joined a major new €8 million European initiative aimed at revolutionizing how personalized cancer treatments like CAR-T cell therapy are delivered in hospitals. Funded by the EU-backed Innovative Health Initiative (IHI), the five-year project—called EASYGEN (Easy workflow integration for gene therapy)—will develop a fully automated system that allows hospitals to manufacture CAR-T therapies on-site in just 24 hours instead of weeks.
A new study has identified three distinct molecular subtypes of follicular lymphoma (FL), offering insights that may shape future precision diagnostics and personalized treatment plans for patients across Asia and the West.
The research was jointly conducted by scientists at BGI Genomics' Institute of Intelligent Medical Research (IIMR) and Sweden's Karolinska Institutet, published in Cell Reports Medicine early August.
The newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will develop a fully automated, hospital-based platform capable of manufacturing personalised cell therapies within a few days. Fresenius SE & Co. KGaA is leading this €8 million EU-backed effort to make CAR-T cell therapy faster, more affordable, and more accessible to patients across Europe. As one of the eighteen consortium partners, EBMT will participate in a study examining current CAR-T treatment processes. EBMT will conduct a literature review on the quality of life of patients treated under existing CAR-T delivery models and will also contribute to patient education and advocacy efforts.
Certain types of biochemical processes can impair the immune system’s ability to recognize and kill cancer cells. Purdue University’s W. Andy Tao and his associates have developed a new way to study these processes. They demonstrated the validity of their method in experiments involving leukemia and rare liver cancer cell lines.
Tao and 10 co-authors published the details of their new method Aug. 1 in the Journal of the American Chemical Society. Their work provides a system for tracking and identifying the various types of proteins and an unheralded but widely secreted class of bioparticles called extracellular vesicles (EVs) that can compromise immunotherapy.